CoChat

Adjunctive Use of Atypical Antipsychotics for Treatment‐Resistant Generalized Anxiety Disorder

Lorenz, Raymond A., Jackson, Cherry W., Saitz, Marianne · 2010 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 32

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Generalized anxiety disorder (GAD) is a common, chronic mental illness that has a significant burden on the patient's quality of life. Treatment for GAD routinely consists of monotherapy with a proven anxiolytic such as an antidepressant or benzodiazepine, but many patients do not respond fully to these drugs, and additional treatment may be needed. Therefore, we reviewed the safety and efficacy of atypical antipsychotics as adjunct therapy to standard GAD pharmacotherapy in patients deemed treatment resistant. We performed a literature search of the MEDLINE database for English‐language articles published from January 1966‐May 2009. Identified articles were evaluated, and only open‐label trials and randomized controlled trials (RCTs) were included in the review. Relevant references from the articles were also evaluated. Only a few reports of large‐scale RCTs that assessed an atypical antipsychotic for treatment‐resistant GAD have been published. Articles were found for five of the eight currently available atypical antipsychotics, but not for asenapine, clozapine, and paliperidone. Several open‐label trials and smaller RCTs support the need for further evaluation of aripiprazole and quetiapine for treatment‐refractory GAD, although one quetiapine trial demonstrated negative results. There is disparate data for risperidone, with one open‐label trial and one small RCT showing positive results and one large RCT showing negative results. One open‐label trial of ziprasidone and one RCT of olanzapine both showed beneficial effects of the drugs. Adverse effects were specific to each agent, with weight gain being the most common, but many studies did not monitor systematically for lipid level, weight, or glucose level changes. Although data suggest efficacy regarding the use of atypical antipsychotics for augmentation of treatment‐refractory GAD, more rigorous studies (large, double‐blind, placebo‐controlled trials) on the safety and efficacy of these agents are needed in order to recommend their use in patients with GAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1592/phco.30.9.942

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 32

Metadata

Authors
Lorenz, R. A., Jackson, C. W., & Saitz, M.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2010-09
Volume
30
Issue
9
Pages
942-951
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W2164941713
Cited by
32
References
11
FWCI
4.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjunctive Use of Atypical Antipsychotics for Treatment‐Resistant Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.1592/phco.30.9.942
The paper
Lorenz, R. A., Jackson, C. W., & Saitz, M. (2010). Adjunctive Use of Atypical Antipsychotics for Treatment‐Resistant Generalized Anxiety Disorder. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.30.9.942

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.